CARDIOVASCULAR MEDICINE

Low prevalence of lipid lowering drug use in older men with established coronary heart disease

P H Whincup¹, J R Emberson², L Lennon², M Walker², O Papacosta², A Thomson²

¹ Department of Public Health Sciences, St George's Hospital Medical School, London SW17 ORE, UK
² Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, UK

Correspondence to:
Correspondence to:
Professor P H Whincup, Department of Public Health Sciences, St George's Hospital Medical School, London SW17 ORE, UK;
p.whincup{at}sghms.ac.uk

Objective: To determine the prevalence and correlates of lipid lowering drug use among older British men with established coronary heart disease (CHD).

Design: Cross sectional survey within a cohort study (British regional heart study) carried out at 20 years of follow up in 1998–2000.

Setting: General practices in 24 British towns.

Participants: 3689 men aged 60–75 years (response rate 76%).

Main outcome measures: Diagnoses of myocardial infarction and angina based on detailed review of general practice records. Lipid lowering drug use and blood cholesterol concentrations ascertained at 20 year follow up examination.

Results: Among 286 men with definite myocardial infarction, 102 (36%) were taking a lipid lowering drug (93 (33%) a statin); among 360 men with definite angina without myocardial infarction, 84 (23%) were taking a lipid lowering drug (78 (21%) a statin). Most men with documented CHD who were not receiving a lipid lowering drug had a total cholesterol concentration of 5.0 mmol/l or more (87% of those with myocardial infarction, 82% with angina). Fewer than half of men with CHD receiving a statin had a total cholesterol concentration below 5.0 mmol/l (45% of those with myocardial infarction and 47% of those with angina). Only one third of the men taking a statin were receiving trial validated dosages. Among men with CHD, a history of revascularisation, more recent diagnosis, and younger age at diagnosis were associated with a higher probability of receiving lipid lowering drug treatment.

Conclusion: Among patients with established CHD, the prevalence of lipid lowering drug use remains low and statin regimens suboptimal. Major improvements in secondary prevention are essential if the benefits of statins are to be realised.

Keywords: statins; lipid lowering drugs; coronary heart disease; survey

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Huang, C, Loewen, P, Pelletier, T, Slater, J, Chung, M (2008). Implementation of proven interventions in general medical inpatients: development and evaluation of a new quality indicator for drug therapy. Qual Saf Health Care 17: 269-274 [Abstract] [Full Text]  
• DeWilde, S, Carey, I M, Richards, N, Whincup, P H, Cook, D G (2008). Trends in secondary prevention of ischaemic heart disease in the UK 1994 2005: use of individual and combination treatment. Heart 94: 83-88 [Abstract] [Full Text]  
• Gnavi, R., Migliardi, A., Demaria, M., Petrelli, A., Caprioglio, A., Costa, G. (2007). Statins prescribing for the secondary prevention of ischaemic heart disease in Torino, Italy. A case of ageism and social inequalities. Eur J Public Health 17: 492-496 [Abstract] [Full Text]  
• Ramsay, S. E., Whincup, P. H., Wannamethee, S. G., Papacosta, O., Lennon, L., Thomas, M. C., Morris, R. W. (2007). Missed opportunities for secondary prevention of cerebrovascular disease in elderly British men from 1999 to 2005: a population-based study. J Public Health (Oxf) 29: 251-257 [Abstract] [Full Text]  
• Rudd, A. G., Hoffman, A., Down, C., Pearson, M., Lowe, D. (2007). Access to stroke care in England, Wales and Northern Ireland: the effect of age, gender and weekend admission. Age Ageing 36: 247-255 [Abstract] [Full Text]  
• Murphy, N F, Simpson, C R, MacIntyre, K, McAlister, F A, Chalmers, J, McMurray, J J V (2006). Prevalence, incidence, primary care burden and medical treatment of angina in Scotland: age, sex and socioeconomic disparities: a population-based study. Heart 92: 1047-1054 [Abstract] [Full Text]  
• Ramsay, S. E., Morris, R. W., Papacosta, O., Lennon, L. T., Thomas, M. C., Whincup, P. H. (2005). Secondary prevention of coronary heart disease in older British men: extent of inequalities before and after implementation of the National Service Framework. J Public Health (Oxf) 27: 338-343 [Abstract] [Full Text]  
• Emberson, J R, Whincup, P H, Lawlor, D A, Montaner, D, Ebrahim, S (2005). Coronary heart disease prevention in clinical practice: are patients with diabetes special? Evidence from two studies of older men and women. Heart 91: 451-455 [Abstract] [Full Text]  
• Walker, M., Whincup, P., Shaper, A. (2004). The British Regional Heart Study 1975-2004. Int J Epidemiol 33: 1185-1192 [Full Text]  
• Ko, D. T., Mamdani, M., Alter, D. A. (2004). Lipid-Lowering Therapy With Statins in High-Risk Elderly Patients: The Treatment-Risk Paradox. JAMA 291: 1864-1870 [Abstract] [Full Text]  
• (2004). Hygieia. J. Epidemiol. Community Health 58: 260-260 [Full Text]  
• Ward, P R, Noyce, P R, St Leger, A S (2004). Are GP practice prescribing rates for coronary heart disease drugs equitable? A cross sectional analysis in four primary care trusts in England. J. Epidemiol. Community Health 58: 89-96 [Abstract] [Full Text]  
• Brophy, J. M., Bourgault, C., Brassard, P. (2003). The use of cholesterol-lowering medications after coronary revascularization. CMAJ 169: 1153-1157 [Abstract] [Full Text]  
• DeWilde, S, Carey, I M, Bremner, S A, Richards, N, Hilton, S R, Cook, D G (2003). Evolution of statin prescribing 1994-2001: a case of agism but not of sexism?. Heart 89: 417-421 [Abstract] [Full Text]  
• Bartlett, C, Davey, P, Dieppe, P, Doyal, L, Ebrahim, S, Egger, M (2003). Women, older persons, and ethnic minorities: factors associated with their inclusion in randomised trials of statins 1990 to 2001. Heart 89: 327-328 [Full Text]  
• (2002). 21st century heart solution may have a sting in the tail. BMJ 325: 184-184 [Full Text]